Switzerland's Santhera Pharma H1 revenue soars on AGAMREE sales, milestones

Overview

• Switzerland specialty pharma firm's H1 revenue rose 101% yr/yr, driven by AGAMREE sales and milestones

• Product sales for H1 climbed 48% yr/yr, reflecting growth in launched European markets

• Net loss for H1 narrowed to CHF 21.5 mln from CHF 38.8 mln a year earlier

Outlook

• Santhera maintains 2026 revenue guidance at CHF 80–90 mln

• Company expects product sales to grow by more than 50% in 2026

• Cash seen broadly stable through year-end, with decline expected in H1 2027 before recovery

Result Drivers

• EU MARKET EXPANSION - Pricing and reimbursement agreements in Spain and Italy enabled AGAMREE commercial launches in four of five major EU markets

• APAC LICENSING DEAL - Exclusive Nxera agreement for Japan, South Korea, Australia and New Zealand drove milestone and royalty income

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Santhera Pharmaceuticals Holding AG is CHF27.50, about 82.4% above its September 29 closing price of CHF15.08

Reuters Recommended Reads

• Sept 29 - Swiss regulator concludes action against Julius Baer, shares surge

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)